Celgene in mRNA translation deal with world's leading cancer charity

14 December 2017

US biotech Celgene (Nasdaq: CELG) has signed a five-year deal with a subsidiary of Cancer Research UK to discover, develop and commercialize new oncology treatments.

Celgene will pay an undisclosed upfront sum and potential milestone payments to Cancer Research Technology (CRT), through which the world’s leading cancer charity carries out its commercial activity.

This collaboration is an expansion of Cancer Research Technology’s theme-based translational model that now encompasses six industry partnerships. This one is focused on mRNA translation, the cellular process of assembling proteins. This research as seen as having the potential to produce treatments targeting a fundamental characteristic of cancer cells.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK